M

Cardiac fibrosis M3 subtype of muscarinic acetylcholine receptor (M3 receptor) beta-site app cleaving enzyme 1 (BACE1) microRNA-29b (miR-29b)

Journal

Cardiovascular diagnosis and therapy
ISSN: 2223-3652
Titre abrégé: Cardiovasc Diagn Ther
Pays: China
ID NLM: 101601613

Informations de publication

Date de publication:
15 Feb 2024
Historique:
received: 20 07 2023
accepted: 24 11 2023
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: ppublish

Résumé

Previous studies have confirmed that choline exerts anti-fibrotic effect in the heart by activating the M Proliferation of cardiac fibroblasts was induced by transforming growth factor (TGF)-β1 The expression of miR-29b decreased when treated with TGF-β1 (P=0.0389) and increased after choline stimulated (P=0.0001). Overexpression of miR-29b could reverse the high expression of collagen I (P<0.0001), α-SMA (P=0.0007), and CTGF (P=0.0038) induced by TGF-β1, whereas inhibition of miR-29b had a tendency to even further increase the expression of fibrosis markers. Meanwhile, inhibition of miR-29b could reverse the anti-fibrotic effect of choline, increasing the expression of collagen I (P=0.0040), α-SMA (P=0.0001), and CTGF (P=0.0185), and promoting the fibroblast proliferation and migration. Moreover, BACE1 protein level, increased after TGF-β1 treatment (P=0.0037) and reversed by overexpression of miR-29b (P=0.0493). Choline could reduce the increase of BACE1 induced by TGF-β1 (P=0.0264), and 4-diphenylacetoxy-N-methyl-piperidine methiodide (4-DAMP) increased the expression of BACE1 (P=0.0060). Furthermore, overexpression of BACE1 could reverse the protective effect of miR-29b in cardiac fibrosis, increasing the protein level of collagen I (P=0.0404). The results suggested that M

Sections du résumé

Background UNASSIGNED
Previous studies have confirmed that choline exerts anti-fibrotic effect in the heart by activating the M
Methods UNASSIGNED
Proliferation of cardiac fibroblasts was induced by transforming growth factor (TGF)-β1
Results UNASSIGNED
The expression of miR-29b decreased when treated with TGF-β1 (P=0.0389) and increased after choline stimulated (P=0.0001). Overexpression of miR-29b could reverse the high expression of collagen I (P<0.0001), α-SMA (P=0.0007), and CTGF (P=0.0038) induced by TGF-β1, whereas inhibition of miR-29b had a tendency to even further increase the expression of fibrosis markers. Meanwhile, inhibition of miR-29b could reverse the anti-fibrotic effect of choline, increasing the expression of collagen I (P=0.0040), α-SMA (P=0.0001), and CTGF (P=0.0185), and promoting the fibroblast proliferation and migration. Moreover, BACE1 protein level, increased after TGF-β1 treatment (P=0.0037) and reversed by overexpression of miR-29b (P=0.0493). Choline could reduce the increase of BACE1 induced by TGF-β1 (P=0.0264), and 4-diphenylacetoxy-N-methyl-piperidine methiodide (4-DAMP) increased the expression of BACE1 (P=0.0060). Furthermore, overexpression of BACE1 could reverse the protective effect of miR-29b in cardiac fibrosis, increasing the protein level of collagen I (P=0.0404).
Conclusions UNASSIGNED
The results suggested that M

Identifiants

pubmed: 38434562
doi: 10.21037/cdt-23-309
pii: cdt-14-01-143
pmc: PMC10904290
doi:

Types de publication

Journal Article

Langues

eng

Pagination

143-157

Informations de copyright

2024 Cardiovascular Diagnosis and Therapy. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-23-309/coif). All authors report that this work was supported by National Natural Science Foundation of China. The authors have no other conflicts of interest to declare.

Auteurs

Wen Li (W)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.

Jie Yu (J)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.

Yilian Yang (Y)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.

Jia Wang (J)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.

Yunqi Liu (Y)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.

Jiapan Wang (J)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.

Juan Hu (J)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.

Ye Yuan (Y)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.
National Key Laboratory of Frigid Zone Cardiovascular Disease, Harbin, China.

Zhimin Du (Z)

Institute of Clinical Pharmacy, the Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province), Harbin, China.
Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.
National Key Laboratory of Frigid Zone Cardiovascular Disease, Harbin, China.

Classifications MeSH